These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
132 related items for PubMed ID: 15489865
1. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A, Solano C, Simonsson B, Sonnen R, Diehl V, Fischer T, Caballero D, Littlewood T, Noppeney R, Schafhausen P, Jost L, Delabarre F, Marcus R. Bone Marrow Transplant; 2004 Dec; 34(11):955-62. PubMed ID: 15489865 [Abstract] [Full Text] [Related]
2. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Kim IH, Park SK, Suh OK, Oh JM. Curr Med Res Opin; 2003 Dec; 19(8):753-9. PubMed ID: 14687447 [Abstract] [Full Text] [Related]
3. Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. Nolan L, Lorigan P, Chilton S, Newman J, Else R, Smith P, Linch D, Sweetenham JW, Johnson PW. Br J Haematol; 2007 Jun; 137(5):436-42. PubMed ID: 17433027 [Abstract] [Full Text] [Related]
5. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia. Takeshita A, Saito H, Toyama K, Horiuchi A, Kuriya S, Furusawa S, Tsuruoka N, Takiguchi T, Matsuda T, Utsumi M, Shiku H, Matsui T, Egami K, Tamura K, Ohno R. Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623 [Abstract] [Full Text] [Related]
7. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses. Suh C, Kim HJ, Kim SH, Kim S, Lee SJ, Lee YS, Kim EK, Kim SB, Lee JS, Kim MW, Kim K, Yoon SS. Transfusion; 2004 Apr; 44(4):533-8. PubMed ID: 15043569 [Abstract] [Full Text] [Related]
8. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H. N Engl J Med; 1995 Jun 22; 332(25):1678-83. PubMed ID: 7539109 [Abstract] [Full Text] [Related]
10. A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone. Karanth M, Chakrabarti S, Lovell RA, Harvey C, Holder K, McConkey CC, McDonald D, Fegan CD, Milligan DW. Bone Marrow Transplant; 2004 Sep 22; 34(5):399-403. PubMed ID: 15273706 [Abstract] [Full Text] [Related]
11. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. de Azevedo AM, Nucci M, Maiolino A, Vigorito AC, Simões BP, Aranha FJ, Tabak DG, Voltarelli J, de Souza CA. Bone Marrow Transplant; 2002 May 22; 29(9):745-51. PubMed ID: 12040471 [Abstract] [Full Text] [Related]
12. Standard- versus high-dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization. Romeo A, Chierichini A, Spagnoli A, Vittori M, Vacca M, Gozzer M, Spadea A, Anaclerico B, Dessanti ML, D'Andrea M, Toglia G, Annino L, Petti MC, Mengarelli A, Arcese W, Rome Transplant Network. Transfusion; 2010 Nov 22; 50(11):2432-46. PubMed ID: 20553434 [Abstract] [Full Text] [Related]
16. A dose-response analysis of lenograstim plus dexamethasone for neutrophil mobilization and collection. Heuft HG, Goudeva L, Pulver N, Grigull L, Schwella N, Blasczyk R. Transfusion; 2005 Apr 22; 45(4):604-12. PubMed ID: 15819683 [Abstract] [Full Text] [Related]
17. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Linch DC, Scarffe H, Proctor S, Chopra R, Taylor PR, Morgenstern G, Cunningham D, Burnett AK, Cawley JC, Franklin IM. Bone Marrow Transplant; 1993 Apr 22; 11(4):307-11. PubMed ID: 7683552 [Abstract] [Full Text] [Related]
18. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Valteau-Couanet D, Faucher C, Aupérin A, Michon J, Milpied N, Boiron JM, Bourhis JH, Gisselbrecht C, Vernant JP, Pinna A, Bendahmane B, Delabarre F, Benhamou E. Bone Marrow Transplant; 2005 Sep 22; 36(6):547-52. PubMed ID: 16007101 [Abstract] [Full Text] [Related]
19. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Stephens DP, Thomas JH, Higgins A, Bailey M, Anstey NM, Currie BJ, Cheng AC. Crit Care Med; 2008 Feb 22; 36(2):448-54. PubMed ID: 18216600 [Abstract] [Full Text] [Related]
20. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Watanabe H, Watanabe T, Suzuya H, Wakata Y, Kaneko M, Onishi T, Okamoto Y, Abe T, Kawano Y, Kagami S, Takaue Y. Bone Marrow Transplant; 2006 Apr 22; 37(7):661-8. PubMed ID: 16489358 [Abstract] [Full Text] [Related] Page: [Next] [New Search]